1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine manufacturers
- ZINC69391
-
- $31.00
-
2026-08-04
- CAS:303094-67-9
- Purity: 99.65%
- Supply Ability: 10g
|
| | 1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine Basic information |
| | 1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine Chemical Properties |
| Melting point | 149-151 °C | | Boiling point | 404.3±55.0 °C(Predicted) | | density | 1.35±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 25 mg/mL (80.83 mM; ultrasonic and warming and heat to 60°C) | | pka | 4.69±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | 1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine Usage And Synthesis |
| Uses | ZINC 69391 is a novel specific Rac1 inhibitor, interferring with the interaction of Rac1 with Dock180, a relevant Rac1 activator in glioma invasion, and to reduce Rac1-GTP levels. | | in vivo | ZINC69391 (25 mg/kg; i.p; daily for 21 days) impairs metastatic lung colonization in a syngeneic animal model[3]. | Animal Model: | Specific pathogen-free female BALB/c inbred mice (bearing F3II cells)[3] | | Dosage: | 25 mg/kg body weight | | Administration: | I.p; daily for 21 days | | Result: | Significantly reduced by about 60% the formation of total metastatic lung colonies.
|
|
| | 1-(4,6-dimethylpyrimidin-2-yl)-3-[2-(trifluoromethyl)phenyl]guanidine Preparation Products And Raw materials |
|